The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLC.
Patil T, Staley A, Nie Y, Sakamoto M, Stalker M, Jurica JM, Koehler K, Cass A, Kuykendall H, Schmitt E, Filar E, Reventaite E, Davies KD, Nijmeh H, Haag M, Yoder BA, Bunn PA, Schenk EL, Aisner DL, Iams WT, Marmarelis ME, Camidge DR.
Patil T, et al. Among authors: haag m.
JTO Clin Res Rep. 2024 Jan 18;5(2):100637. doi: 10.1016/j.jtocrr.2024.100637. eCollection 2024 Feb.
JTO Clin Res Rep. 2024.
PMID: 38361741
Free PMC article.